NeuroOne Medical Technologies Corp Dossier - Source-backed chat

NeuroOne Medical Technologies Corp

NMTCNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.67

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.99Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $9M

Enterprise Value $6.2M

Shares Outstanding 8.7M diluted

Next Earnings Date16 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NeuroOne Medical Technologies (NMTC) is a commercial-stage medical technology company with a highly innovative thin-film electrode platform targeting brain, pain, and advanced drug delivery markets. While the company has demonstrated strong sequential product revenue growth driven by its FDA-cleared OneRF Ablation System, it faces severe near-term liquidity constraints. With cash projected to fund operations only through September 2026, a recent material restatement of its Q2 fiscal 2026 results due to internal control deficiencies, and substantial doubt regarding its ability to continue as a going concern, the stock carries elevated risk. A 'Hold' recommendation is warranted until the company secures non-dilutive strategic funding or executes a successful capital raise to stabilize its balance sheet.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$7.27

High · most bullish analyst$8.80

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The bear case materializes if NeuroOne fails to secure additional capital before September 2026, leading to severe operational disruption or highly dilutive equity financing at depressed valuations. Commercial momentum stalls due to slower-than-expected hospital adoption or further internal control failures that damage investor confidence.

Base CaseCentral scenario

$3.5055%

The base case assumes NeuroOne achieves its guided fiscal 2026 product revenue of at least $10.5 million, supported by Zimmer Biomet's distribution. The company successfully secures dilutive or non-dilutive financing before September 2026 to extend its runway, while gradually resolving its internal control weaknesses.

Bull CaseUpside scenario

$8.0025%

The bull case is driven by rapid commercial adoption of the OneRF Ablation System and the newly cleared OneRF Trigeminal Nerve Ablation System for facial pain. Strategic partnerships in advanced drug delivery (e.g., gene/cell therapy and glioblastoma) generate significant upfront non-dilutive licensing revenue, resolving going-concern doubts and accelerating path to profitability.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Innovative, FDA-cleared thin-film electrode platform (Evo Cortical, Evo sEEG, OneRF, and OneRF Trigeminal Nerve Ablation Systems) offering superior precision and patient outcomes.
Exclusive global distribution agreement with Zimmer Biomet for the OneRF Ablation System, providing strong commercial validation and scaling support.
Expansion into high-value adjacent markets including chronic pain management and advanced drug delivery (preclinical devices already sold to a major pharmaceutical partner).

Key Investment Risks

Going concern risk with current cash runway projected to fund operations only through September 2026.
Material weakness in internal controls over financial reporting, as evidenced by the restatement of Q2 fiscal 2026 results due to duplicated revenue entries.
High customer concentration risk, with Zimmer Biomet accounting for the vast majority of product revenues.

Thesis Invalidation Triggers

Failure to secure additional financing or strategic partnerships by September 2026.
Termination or material negative modification of the Zimmer Biomet distribution agreement.
Inability to regain or maintain compliance with Nasdaq listing requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.